Chloroquine Phosphate

Porphyria Cutanea Tarda, Sarcoidosis, prophylaxis of Malaria + 6 more
Treatment
6 FDA approvals
20 Active Studies for Chloroquine Phosphate

What is Chloroquine Phosphate

ChloroquineThe Generic name of this drug
Treatment SummaryChloroquine is a medication that was originally developed in the 1940s to treat malaria. It was the go-to treatment until more effective drugs such as pyrimethamine, artemisinin, and mefloquine were invented. In recent years, chloroquine and its derivative hydroxychloroquine have been used to treat other conditions such as HIV, lupus, and rheumatoid arthritis. In 2020, the FDA revoked its emergency use authorization for hydroxychloroquine and chloroquine for the treatment of COVID-19. Chloroquine was first approved by the FDA in
Aralenis the brand name
image of different drug pills on a surface
Chloroquine Phosphate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Aralen
Chloroquine
1972
22

Approved as Treatment by the FDA

Chloroquine, also called Aralen, is approved by the FDA for 6 uses which include acute, uncomplicated Malaria and Plasmodium Infections .
acute, uncomplicated Malaria
Plasmodium Infections
Malaria
Malaria
prophylaxis of Malaria
Extraintestinal Amebiasis

Effectiveness

How Chloroquine Phosphate Affects PatientsChloroquine stops the production of a toxic compound in the _Plasmodium_ species, which can stay in the body for up to 60 days. People taking chloroquine long term or in high doses may experience vision problems, muscle weakness, and toxicity in children, so they should be warned about these potential side effects.
How Chloroquine Phosphate works in the bodyChloroquine stops the growth of malaria by preventing the parasite from converting heme into hemazoin. The drug moves through cell walls, enters organelles like endosomes and lysosomes, and becomes protonated, trapping it in these organelles. This raises the pH levels and stops viruses from fusing and entering the cell. It also blocks the glycosylation of ACE2, a receptor that SARS-CoV and SARS-CoV-2 use to enter cells. This makes it harder for the virus to interact with the spike protein, which prevents it from entering the cell.

When to interrupt dosage

The proposed measure of Chloroquine Phosphate is dependent upon the indicated condition, including Porphyria Cutanea Tarda, Actinic prurigo and acute, uncomplicated Malaria. The amount of dosage is contingent upon the method of administration, as featured in the table below.
Condition
Dosage
Administration
Lupus Erythematosus, Discoid
, 250.0 mg, 500.0 mg
, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral
Extraintestinal Amebiasis
, 250.0 mg, 500.0 mg
, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral
Malaria
, 250.0 mg, 500.0 mg
, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral
Rheumatoid Arthritis
, 250.0 mg, 500.0 mg
, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral
Porphyria Cutanea Tarda
, 250.0 mg, 500.0 mg
, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral
Sarcoidosis
, 250.0 mg, 500.0 mg
, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral
prophylaxis of Malaria
, 250.0 mg, 500.0 mg
, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral
Malaria
, 250.0 mg, 500.0 mg
, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral
Actinic prurigo
, 250.0 mg, 500.0 mg
, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral

Warnings

Chloroquine Phosphate Contraindications
Condition
Risk Level
Notes
visual field changes
Do Not Combine
retinal changes
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Chloroquine may interact with Pulse Frequency
There are 20 known major drug interactions with Chloroquine Phosphate.
Common Chloroquine Phosphate Drug Interactions
Drug Name
Risk Level
Description
Acepromazine
Major
The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Acepromazine.
Aceprometazine
Major
The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Aceprometazine.
Acetophenazine
Major
The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Acetophenazine.
Agalsidase beta
Major
The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Chloroquine.
Alimemazine
Major
The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Alimemazine.
Chloroquine Phosphate Toxicity & Overdose RiskSigns of overdosing on this drug include headaches, drowsiness, vision problems, nausea, vomiting, shock, seizures, difficulty breathing, heart failure, and low potassium levels. Treatment for this drug overdose includes inducing vomiting, stomach pumping, and administering activated charcoal.
image of a doctor in a lab doing drug, clinical research

Chloroquine Phosphate Novel Uses: Which Conditions Have a Clinical Trial Featuring Chloroquine Phosphate?

Currently, 92 active trials are assessing the utility of Chloroquine Phosphate in providing relief for Porphyria Cutanea Tarda, Rheumatoid Arthritis and Malaria prophylaxis.
Condition
Clinical Trials
Trial Phases
Actinic prurigo
0 Actively Recruiting
Malaria
0 Actively Recruiting
Porphyria Cutanea Tarda
0 Actively Recruiting
Lupus Erythematosus, Discoid
8 Actively Recruiting
Phase 2, Phase 3, Phase 1
Extraintestinal Amebiasis
0 Actively Recruiting
Rheumatoid Arthritis
55 Actively Recruiting
Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1
Malaria
0 Actively Recruiting
Sarcoidosis
5 Actively Recruiting
Phase 4, Phase 2, Not Applicable
prophylaxis of Malaria
0 Actively Recruiting

Chloroquine Phosphate Reviews: What are patients saying about Chloroquine Phosphate?

3Patient Review
3/16/2010
Chloroquine Phosphate for Osteoporosis
This treatment really helped me. I'm grateful for modern medicine.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about chloroquine phosphate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of chloroquine phosphate?

"You may have a headache, nausea, loss of appetite, diarrhea, upset stomach, stomach pain, rash, or itching."

Answered by AI

What is chloroquine phosphate used for?

"Chloroquine phosphate is a medicine used to prevent or treat certain types of malaria and to treat some types of extraintestinal amoeba infections. It is sold under the brand name Aralen, and it is also available in generic form."

Answered by AI

What is the main side effect of chloroquine?

"The most common side effects of chloroquine are nausea, vomiting, diarrhoea, stomach cramps and headache. Less common side effects include changes in mood or behaviour, hair loss and skin rashes."

Answered by AI

Is it safe to take chloroquine phosphate?

"If you take this medicine for a long time, it may make your muscles weak. Talk to your doctor right away if you have muscle weakness while using this medicine. This medicine is very dangerous for children, and even a small amount can lead to an overdose. Keep this medicine away from children."

Answered by AI

Clinical Trials for Chloroquine Phosphate

Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada
People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What the Investigators Think: The investigators believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What the Investigators are Doing: The investigators will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing the investigators will look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. The investigators will also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: The investigators have already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. The investigators have also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, the investigators need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.
Phase 4
Waitlist Available
Sunnybrook Health Sciences Centre (+4 Sites)
Image of California Clinical Trials Medical Group in Glendale, United States.

NTR-1011 for Lupus and Rheumatoid Arthritis

18 - 75
All Sexes
Glendale, CA
This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are to determine the safety profile of NTR-1011 across subcutaneous and intravenous dose levels, understand how the drug behaves in the body, characterize its biological activity through relevant pharmacodynamic markers, assess the potential for immune responses to treatment, and explore early signals of clinical benefit in autoimmune disease settings. This is a randomized, double blind, placebo controlled study that begins with a single ascending dose evaluation in healthy volunteers followed by a multiple dose assessment in patients. The design is intended to define the highest safe and well tolerated dose, establish a robust PK and PD baseline, and generate initial patient level evidence to support dose selection and advancement into subsequent clinical development.
Phase 1
Recruiting
California Clinical Trials Medical GroupHakop Gevorkyan, MDNeutrolis
Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention
Recruiting
Has No Placebo
Weill Cornell Medical CollegeIris Y Navarro-Millán, MDBristol-Myers Squibb
Have you considered Chloroquine Phosphate clinical trials? We made a collection of clinical trials featuring Chloroquine Phosphate, we think they might fit your search criteria.Go to Trials
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Image of University of Minnesota Medical School, Division of Rheumatic and Autoimmune Diseases in Minneapolis, United States.

Ultrasound Therapy for Rheumatoid Arthritis

18+
All Sexes
Minneapolis, MN
The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs). The non-invasive study device delivers ultrasound stimulation to the spleen to reduce inflammation. The study will enroll at least 60 participants at up to 8 sites. There will be three arms consisting of two active stimulation groups (treatment) and one non-active stimulation group (sham-control). After completing the double-blinded primary endpoint assessment period at Week 12, there will be a one-way crossover of control participants to active stimulation and an additional 12 week follow-up with all participants to evaluate long-term outcomes.
Recruiting
Drug
University of Minnesota Medical School, Division of Rheumatic and Autoimmune DiseasesDaniel ZachsSecondWave Systems Inc.
Have you considered Chloroquine Phosphate clinical trials? We made a collection of clinical trials featuring Chloroquine Phosphate, we think they might fit your search criteria.Go to Trials
Image of Cleveland Clinic in Cleveland, United States.

Virtual Patient Groups for Sarcoidosis

18+
All Sexes
Cleveland, OH
This research study is testing whether Mindfulness-Based Cognitive Therapy (MBCT) can help reduce fatigue in people with sarcoidosis. The study will also look at whether MBCT can improve symptoms of anxiety and depression. Participants will be placed into one of two groups: * One group will take part in an 8-week virtual MBCT program, attend weekly online sessions, keep a daily mindfulness journal, and complete surveys about fatigue, anxiety, and depression. * The other group will join a virtual support group once a month for 6 months and complete the same surveys. The goal is to see which approach is more helpful for improving fatigue and mental well-being in people with sarcoidosis.
Waitlist Available
Has No Placebo
Cleveland ClinicLogan J Harper, MD
Image of St. Lawrence Health in Potsdam, United States.

Primary Care for Rheumatoid Arthritis

18+
All Sexes
Potsdam, NY
Rheumatoid arthritis (RA) is a complex autoimmune disease where the immune system attacks healthy joint tissue; causing pain, swelling, and stiffness of the joints. This disease effects lots of people in the US and can lead to major joint damage if not properly treated. In rural areas like northern NY, these are underserved areas for RA patients, thus many patients struggle to get the appropriate care. This model is testing whether primary care providers (PCP) can safely and effectively provide stable RA patients with the proper treatment rather than send them to a specialist. PCPs were trained through classes, case reviews, and a final exam. Patients will be randomly assigned to either see a trained PCP or their normal rheumatologist at the rheumatology clinic. This study will examine how patients are doing over a year using medical exams and patient feedback. If this model proves to be successful, it will make RA treatment easier and more affordable for patients.
Recruiting
Has No Placebo
St. Lawrence HealthEyal Kedar, MD
Image of Pender Community Health Centre in Vancouver, Canada.

Personalized Outreach for Rheumatic Diseases

18+
All Sexes
Vancouver, Canada
The primary goal of this study is to determine whether providing patient honoraria and/or outreach services can improve the attendance rate of appointments at an inner city rheumatology clinic in Vancouver, British Columbia. The main question it aims to answer are: * Does providing a financial honorarium ($20 for each follow-up appointment with completed bloodwork) improve attendance rate at an inner city rheumatology clinic? * Does providing a personalized outreach service for rheumatic diseases improve attendance rate at an inner city rheumatology clinic? The researchers will compare providing patient honoraria to providing both honoraria and outreach services, and compare each of these to the regular appointment schedule without honoraria or outreach. Participants will: * Undergo randomization to receive honoraria or honoraria and outreach services together * Complete surveys about their health and understanding of their rheumatic disease at baseline, 3-month, and 6-month intervals * Visit the clinic every month for check-ups and monitoring bloodwork if they are started on immunosuppressants for their condition
Waitlist Available
Has No Placebo
Pender Community Health CentreBrent R Ohata, MD
Have you considered Chloroquine Phosphate clinical trials? We made a collection of clinical trials featuring Chloroquine Phosphate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security